NVAX
Novavax Inc
NASDAQ · Biotechnology
$8.25
+0.38 (+4.83%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 728.37M | 865.97M | 465.29M | 441.16M | 496.93M |
| Net Income | -200,198,760 | -214,218,147 | -6,820,545 | -6,729,988 | -7,016,912 |
| EPS | — | — | — | — | — |
| Profit Margin | -27.5% | -26.1% | -1.5% | -1.5% | -1.4% |
| Rev Growth | -15.9% | -15.9% | +3.2% | +6.7% | +13.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 286.44M | 286.44M | 746.45M | 676.10M | 713.41M |
| Total Equity | 383.87M | 383.87M | 642.33M | 690.04M | 696.43M |
| D/E Ratio | 0.75 | 0.75 | 1.16 | 0.98 | 1.02 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -115,358,035 | -130,293,821 | -9,193,836 | -8,036,743 | -8,599,324 |
| Free Cash Flow | — | — | -7,451,233 | -9,195,591 | -10,064,458 |